Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilnidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 8/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 7/20 | 0.69 |
| ▸ | CACNA1D known ✓ | Q01668 | 7/20 | 0.69 |
| ▸ | CACNA1S known ✓ | Q13698 | 7/20 | 0.69 |
| ▸ | CACNA1B | Q00975 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilnidipine SCHEMBL25550 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL29367885 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL31398437 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL25551 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL30209784 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL28356318 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL29248832 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL27852253 | 0.97 | CACNA1C (0.95) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL29141421 | 0.95 | CACNA1C (0.90) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| SCHEMBL10739961 | 0.94 | CACNA1B (0.94) | CACNA1CCACNA1BMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | claimed |
| EP-0161877-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1991-05-29 | — | — | EP | claimed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-0161877-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1991-05-29 | — | — | EP | disclosed |
| US-4672068-A | Antihypertensive 1,4-dihydropyridines having a conjugated ester | FUJIREBIO KABUSHIKI KAISHA (JP) | 1987-06-09 | — | — | US | disclosed |
| EP-0161877-A2 | 1,4-dihydropyridine derivatives, methods for their production and pharmaceutical compositions comprising the same | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | CACNA1C 1/4885CACNA1F 6/4885CACNA1D 4/4885 |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | CACNA1C 1/4885CACNA1F 6/4885CACNA1D 4/4885 |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | CACNA1C 3611/4885CACNA1F 3667/4885CACNA1D 3865/4885 |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | CACNA1C 1/4885CACNA1F 6/4885CACNA1D 4/4885 |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | CACNA1C 2/4885CACNA1F 6/4885CACNA1D 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.